Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 1, 2000, Pages 83-88

  Giannakenas, C ^a,b   Kalofonos, H P ^a   Apostolopoulos, D J ^a   Zarakovitis, J ^a   Kosmas, C ^a   Vassilakos, P J ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b NONE   (Greece)

Author keywords

Bone metastases; Cancer; Pain; Palliation; Re 186 HEDP

Indexed keywords

ETIDRONIC ACID RE 186;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PAIN, INTRACTABLE; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 0034051261     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200002000-00023     Document Type: Article

References (36)

1. Rubens RD. The nature of metastatic bone disease. In: Rubens RD, Fogelman I, eds. Bone metastases: diagnosis and treatment. London: Springer-Verlag, 1991:1-10.
2. Lote K, Walloe A, Bersand A. Bone metastasis. Prognosis, diagnosis and treatment. Acta Radiol Oncol 1986;25:227-32.
3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
4. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21: 337-44.
5. Hendrickson FR, Shehata WM, Kirchner AB. Radiation therapy for osseous metastasis. Int J Radiat Oncol Biol Phys 1976;1: 275-8.
6. Volkert WA, Goeckeler WF, Erhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay properties considerations. J Nucl Med 1991;32:174-85.
7. Spencer RP. Shorter lived radionuclides in therapy. Nucl Med Biol 1987;14:537-8.
8. Mausner LF, Svrivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993;20:503-9.
9. Lebedeva LI, Akhmamet'eva EM. Comparative dynamics of elimination of potential chromosome damage in mouse bone marrow cells after low and moderate doses of radiation. Genetika 1997;33: 1362-6.
10. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261-9.
11. Turner JH, Claringbold PG, Berger JD, Martindale AA, Glancy JR. 153Sm-EDTMP and melphalan chemotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl Med Commun 1992;13:321-9.
12. Englaro EE, Schroder LE, Thomas SR, Williams CC, Maxon HR. Safety and efficacy of repeated sequential administrations of Re186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clin Nucl Med 1992;17:41-4.
13. Bayouth JE, Macey DJ. Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Med Phys 1993;20:1089-96.
14. Lewington VJ. Targeted radionuclide therapy for hone metastases. Eur J Nucl Med 1993;20:66-74.
15. Clarke SEM. Radionuclide therapy in oncology. Cancer Treat Rev 1994;20:51-71.
16. Gilbert HA, Kagan AR, Nussbaum H, et al. Evaluation of radiation therapy for bone metastases: pain relief and quality of life. Am J Roentgenol 1977;129:1095-6.
17. Kuban DA, Delbridge T, El-Mahdi AM, Schellhammer PF. Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. J Urol 1989;141:572-4.
18. Fitzpatrick PJ, Rider WD, Half-body radiotherapy. Int J Radiat Oncol Biol Phys 1976;1:197-207.
19. Wilkins MF, Keen CW. Hemi-body radiotherapy in the management of metastatic carcinoma. Clin Radiol 1987;38:267-8.
20. Hoskins PJ. Palliation of hone metastases. Eur J Cancer 1991;27: 950-1.
21. Hoskins PJ. Radiotherapy in the management of hone metastases. In: Rubens RD, Fogelman I, eds. Bone metastases: diagnosis and treatment. London: Springer-Verlag, 1991:171-85.
22. Perez CA, Cosmatos D, Garcia DM, Eisbruch AE, Poulter CA. Irradiation in relapsing carcinoma of the prostate. Cancer 1993; 71:1110-22.
23. Maxon HR, Schroder LE, Thomas SR, et al. Re-186-(Sn)-HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176:155-9.
24. Zonnenberg BA, de Klerk JMH, van Rijk PP, et al. Re-186-HEDP for treatment of painful hone metastases in patients with metastatic prostate or breast cancer. Preliminary results [abstract]. J Nucl Med 1991;32:1082.
25. Zonnenberg BA, de Klerk JMH, Quirijnen JMSP, van Rijk PP. Initial results of a dose escalation study with 186Re-HEDP. Preliminary results [abstract]. Eur J Cancer 1991;27(suppl 2):287.
26. Turner JH, Martindale AA, Storby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med 1989;15:784-95.
27. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D'Alessandro T. Tin-117m(+4)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med 1995;36:725-9.
28. Robinson RG, Preston DF, Spicer JA, et al. Radionuclide therapy of intractable bone pain: emphasis in strontium-89. Semin Nucl Med 1992;22:28-32.
29. Hall SM, Buzdar AU, Blumenschein GR. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer 1983;32:180-4.
30. Butes T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 1992;23:217-21.
31. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomised phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
32. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210-4.
33. Pienta KJ, Naik H, Lehr JE. Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology 1996;48:164-70.
34. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997;24:S15-72-7.
35. Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995;22:41-5.
36. Cancer Therapy Evaluation Program, Division of Cancer Treatments. Common toxicity criteria: guidelines for reporting of adverse drug reactions. Bethesda, MD: National Cancer Institute, 1988.